The hormonal intrauterine devices (iuds) market size has grown rapidly in recent years. It will grow from $2.87 billion in 2025 to $3.18 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing awareness of family planning options, expansion of women’s reproductive healthcare programs, rising preference for long-term contraception, availability of hormone-based devices, support from public health initiatives.
The hormonal intrauterine devices (iuds) market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing demand for non-surgical contraceptive solutions, rising focus on menstrual health management, expansion of access in emerging markets, growing investments in women’s health technologies, increasing innovation in hormone delivery systems. Major trends in the forecast period include increasing adoption of low-dose hormonal iuds, rising demand for long-acting reversible contraceptives, growing preference for frameless device designs, expansion of therapeutic iud applications, enhanced focus on patient comfort and safety.
The rise in unwanted pregnancies is expected to drive the growth of the hormonal intrauterine devices (IUDs) market in the coming years. Unwanted pregnancies are those that occur without planning or desire at the time of conception. They can result from various factors, including contraceptive failure, limited access to birth control, incorrect use of contraception, or sexual violence. Restricted access to effective contraception increases the likelihood of unwanted pregnancies by limiting individuals’ control over their reproductive choices. Hormonal IUDs are highly effective in preventing pregnancy, with a failure rate below 1%. They offer long-term protection, ranging from three to seven years depending on the type, making them a dependable option for individuals seeking to avoid unwanted pregnancies. For example, according to the Society for Family Planning, a US-based professional organization, abortions in the United States rose to 1.14 million in 2024, up from 1.05 million in 2023. Consequently, the increase in unwanted pregnancies is propelling the demand for hormonal IUDs.
Major companies in the hormonal intrauterine devices market are focusing on developing advanced solutions, such as levonorgestrel IUDs, which help reduce menstrual bleeding and cramps. Levonorgestrel IUDs are long-term contraceptive devices inserted into the uterus that gradually release the hormone levonorgestrel to prevent pregnancy. For instance, in October 2024, Medicines360, a US-based nonprofit organization, launched Avibela, a 52 mg levonorgestrel IUD, in Zambia. It provides dual benefits: up to eight years of pregnancy prevention and up to five years of relief from heavy menstrual bleeding. Its contraceptive effect is achieved by thickening cervical mucus to block sperm from reaching the uterus, while its therapeutic effect reduces menstrual flow by thinning the uterine lining.
In January 2024, Medicines360 partnered with DKT WomanCare Global to expand the accessibility of the affordable hormonal IUD Avibela. This collaboration aimed to increase awareness and reach, particularly in underserved regions, improving global sexual and reproductive health. DKT WomanCare Global, a France-based organization, focuses on enhancing the availability, accessibility, and affordability of sexual and reproductive health products for women.
Major companies operating in the hormonal intrauterine devices (iuds) market are Bayer AG, Organon & Companies, Gedeon Richter Plc, Meril Life Science Pvt Ltd., Teva UK Limited, Medicines360, HLL Lifecare Limited, Pregna International Ltd., DKT WomanCare Global, SMB Corporation of India, Oy Leiras, OCON Healthcare, Bayer Healthcare Pharmaceuticals, CooperSurgical Inc., Mithra Pharmaceuticals, Shanghai Dahua Medical Apparatus Co. Ltd., Beijing Zizhu Pharmaceutical Co. Ltd., Shanghai Jiansheng Medical Devices Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Shanghai Chuangling Medical Devices Co. Ltd.
North America was the largest region in the hormonal intrauterine devices (IUDs) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormonal intrauterine devices (iuds) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hormonal intrauterine devices (iuds) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hormonal intrauterine devices market by increasing costs of imported medical-grade polymers, hormone compounds, packaging materials, and precision manufacturing equipment. Healthcare providers in North America and Europe are most affected due to reliance on imported device components, while Asia-Pacific faces pricing pressure on export-oriented production. These tariffs are contributing to higher device procurement costs and slower market penetration in cost-sensitive regions. However, they are also encouraging localized manufacturing, regional supply chain development, and domestic production of hormonal IUDs.
The hormonal intrauterine devices (iuds) market research report is one of a series of new reports that provides hormonal intrauterine devices (iuds) market statistics, including hormonal intrauterine devices (iuds) industry global market size, regional shares, competitors with a hormonal intrauterine devices (iuds) market share, detailed hormonal intrauterine devices (iuds) market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal intrauterine devices (iuds) industry. This hormonal intrauterine devices (iuds) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hormonal intrauterine devices (IUDs) are small, T-shaped plastic devices that are inserted into the uterus and release progestin, a synthetic hormone. These devices prevent pregnancy by thickening cervical mucus to block sperm, thinning the uterine lining to impede implantation, and sometimes suppressing ovulation. Additionally, they can reduce menstrual bleeding and cramping, and in some cases, may stop periods altogether.
The primary types of hormonal IUDs include 13-milligram, 19-milligram, and 52-milligram hormonal IUDs. The 13-milligram hormonal IUDs, which release a low dose of hormones for up to three years, are becoming increasingly popular among women seeking long-acting contraceptive options with lower hormone exposure. The design of these devices varies, including framed and frameless IUDs, and they feature different hormone types such as levonorgestrel-releasing and progesterone-releasing IUDs. These options cater to various age groups, including those aged 20-24, 25-34, and 35-44, among other applications.
The hormonal intrauterine devices (IUDs) market consists of sales of hormone reservoir, strings, and insertion or removal instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hormonal intrauterine devices (iuds) market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing demand for non-surgical contraceptive solutions, rising focus on menstrual health management, expansion of access in emerging markets, growing investments in women’s health technologies, increasing innovation in hormone delivery systems. Major trends in the forecast period include increasing adoption of low-dose hormonal iuds, rising demand for long-acting reversible contraceptives, growing preference for frameless device designs, expansion of therapeutic iud applications, enhanced focus on patient comfort and safety.
The rise in unwanted pregnancies is expected to drive the growth of the hormonal intrauterine devices (IUDs) market in the coming years. Unwanted pregnancies are those that occur without planning or desire at the time of conception. They can result from various factors, including contraceptive failure, limited access to birth control, incorrect use of contraception, or sexual violence. Restricted access to effective contraception increases the likelihood of unwanted pregnancies by limiting individuals’ control over their reproductive choices. Hormonal IUDs are highly effective in preventing pregnancy, with a failure rate below 1%. They offer long-term protection, ranging from three to seven years depending on the type, making them a dependable option for individuals seeking to avoid unwanted pregnancies. For example, according to the Society for Family Planning, a US-based professional organization, abortions in the United States rose to 1.14 million in 2024, up from 1.05 million in 2023. Consequently, the increase in unwanted pregnancies is propelling the demand for hormonal IUDs.
Major companies in the hormonal intrauterine devices market are focusing on developing advanced solutions, such as levonorgestrel IUDs, which help reduce menstrual bleeding and cramps. Levonorgestrel IUDs are long-term contraceptive devices inserted into the uterus that gradually release the hormone levonorgestrel to prevent pregnancy. For instance, in October 2024, Medicines360, a US-based nonprofit organization, launched Avibela, a 52 mg levonorgestrel IUD, in Zambia. It provides dual benefits: up to eight years of pregnancy prevention and up to five years of relief from heavy menstrual bleeding. Its contraceptive effect is achieved by thickening cervical mucus to block sperm from reaching the uterus, while its therapeutic effect reduces menstrual flow by thinning the uterine lining.
In January 2024, Medicines360 partnered with DKT WomanCare Global to expand the accessibility of the affordable hormonal IUD Avibela. This collaboration aimed to increase awareness and reach, particularly in underserved regions, improving global sexual and reproductive health. DKT WomanCare Global, a France-based organization, focuses on enhancing the availability, accessibility, and affordability of sexual and reproductive health products for women.
Major companies operating in the hormonal intrauterine devices (iuds) market are Bayer AG, Organon & Companies, Gedeon Richter Plc, Meril Life Science Pvt Ltd., Teva UK Limited, Medicines360, HLL Lifecare Limited, Pregna International Ltd., DKT WomanCare Global, SMB Corporation of India, Oy Leiras, OCON Healthcare, Bayer Healthcare Pharmaceuticals, CooperSurgical Inc., Mithra Pharmaceuticals, Shanghai Dahua Medical Apparatus Co. Ltd., Beijing Zizhu Pharmaceutical Co. Ltd., Shanghai Jiansheng Medical Devices Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Shanghai Chuangling Medical Devices Co. Ltd.
North America was the largest region in the hormonal intrauterine devices (IUDs) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormonal intrauterine devices (iuds) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hormonal intrauterine devices (iuds) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hormonal intrauterine devices market by increasing costs of imported medical-grade polymers, hormone compounds, packaging materials, and precision manufacturing equipment. Healthcare providers in North America and Europe are most affected due to reliance on imported device components, while Asia-Pacific faces pricing pressure on export-oriented production. These tariffs are contributing to higher device procurement costs and slower market penetration in cost-sensitive regions. However, they are also encouraging localized manufacturing, regional supply chain development, and domestic production of hormonal IUDs.
The hormonal intrauterine devices (iuds) market research report is one of a series of new reports that provides hormonal intrauterine devices (iuds) market statistics, including hormonal intrauterine devices (iuds) industry global market size, regional shares, competitors with a hormonal intrauterine devices (iuds) market share, detailed hormonal intrauterine devices (iuds) market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal intrauterine devices (iuds) industry. This hormonal intrauterine devices (iuds) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hormonal intrauterine devices (IUDs) are small, T-shaped plastic devices that are inserted into the uterus and release progestin, a synthetic hormone. These devices prevent pregnancy by thickening cervical mucus to block sperm, thinning the uterine lining to impede implantation, and sometimes suppressing ovulation. Additionally, they can reduce menstrual bleeding and cramping, and in some cases, may stop periods altogether.
The primary types of hormonal IUDs include 13-milligram, 19-milligram, and 52-milligram hormonal IUDs. The 13-milligram hormonal IUDs, which release a low dose of hormones for up to three years, are becoming increasingly popular among women seeking long-acting contraceptive options with lower hormone exposure. The design of these devices varies, including framed and frameless IUDs, and they feature different hormone types such as levonorgestrel-releasing and progesterone-releasing IUDs. These options cater to various age groups, including those aged 20-24, 25-34, and 35-44, among other applications.
The hormonal intrauterine devices (IUDs) market consists of sales of hormone reservoir, strings, and insertion or removal instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hormonal Intrauterine Devices (IUDs) Market Characteristics
3. Hormonal Intrauterine Devices (IUDs) Market Supply Chain Analysis
4. Global Hormonal Intrauterine Devices (IUDs) Market Trends and Strategies
5. Hormonal Intrauterine Devices (IUDs) Market Analysis of End Use Industries
7. Global Hormonal Intrauterine Devices (IUDs) Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hormonal Intrauterine Devices (IUDs) Total Addressable Market (TAM) Analysis for the Market
9. Hormonal Intrauterine Devices (IUDs) Market Segmentation
13 Milligram Hormonal Intrauterine Devices, 19 Milligram Hormonal Intrauterine Devices, 52 Milligram Hormonal Intrauterine Devices
10. Hormonal Intrauterine Devices (IUDs) Market Regional and Country Analysis
11. Asia-Pacific Hormonal Intrauterine Devices (IUDs) Market
12. China Hormonal Intrauterine Devices (IUDs) Market
13. India Hormonal Intrauterine Devices (IUDs) Market
14. Japan Hormonal Intrauterine Devices (IUDs) Market
15. Australia Hormonal Intrauterine Devices (IUDs) Market
16. Indonesia Hormonal Intrauterine Devices (IUDs) Market
17. South Korea Hormonal Intrauterine Devices (IUDs) Market
18. Taiwan Hormonal Intrauterine Devices (IUDs) Market
19. South East Asia Hormonal Intrauterine Devices (IUDs) Market
20. Western Europe Hormonal Intrauterine Devices (IUDs) Market
21. UK Hormonal Intrauterine Devices (IUDs) Market
22. Germany Hormonal Intrauterine Devices (IUDs) Market
23. France Hormonal Intrauterine Devices (IUDs) Market
24. Italy Hormonal Intrauterine Devices (IUDs) Market
25. Spain Hormonal Intrauterine Devices (IUDs) Market
26. Eastern Europe Hormonal Intrauterine Devices (IUDs) Market
27. Russia Hormonal Intrauterine Devices (IUDs) Market
28. North America Hormonal Intrauterine Devices (IUDs) Market
29. USA Hormonal Intrauterine Devices (IUDs) Market
30. Canada Hormonal Intrauterine Devices (IUDs) Market
31. South America Hormonal Intrauterine Devices (IUDs) Market
32. Brazil Hormonal Intrauterine Devices (IUDs) Market
33. Middle East Hormonal Intrauterine Devices (IUDs) Market
34. Africa Hormonal Intrauterine Devices (IUDs) Market
36. Hormonal Intrauterine Devices (IUDs) Market Competitive Landscape and Company Profiles
37. Hormonal Intrauterine Devices (IUDs) Market Other Major and Innovative Companies
40. Hormonal Intrauterine Devices (IUDs) Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Hormonal Intrauterine Devices (IUDs) Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hormonal intrauterine devices (iuds) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hormonal intrauterine devices (iuds)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hormonal intrauterine devices (iuds) market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: 13 Milligram Hormonal Intrauterine Devices; 19 Milligram Hormonal Intrauterine Devices; 52 Milligram Hormonal Intrauterine Devices2) By Device Design: Framed Intrauterine Devices; Frameless Intrauterine Devices
3) By Hormone Type: Levonorgestrel Releasing Intrauterine Devices; Progesterone Releasing Intrauterine Devices
4) By Application: Age 20-24; Age 25-34; Age 35-44; Other Applications
Subsegments:
1) By 13 Milligram Hormonal Intrauterine Devices: Low-Dose 13 Mg IUDs; Specialty 13 Mg IUDs For Specific Conditions2) By 19 Milligram Hormonal Intrauterine Devices: Low-Dose 19 Mg IUDs; Specialty 19 Mg IUDs For Specific Conditions
3) By 52 Milligram Hormonal Intrauterine Devices: Standard 52 Mg IUDs; Extended-Release 52 Mg IUDs; Specialty 52 Mg IUDs For Heavy Menstrual Bleeding Or Endometriosis
Companies Mentioned: Bayer AG; Organon & Companies; Gedeon Richter Plc; Meril Life Science Pvt Ltd.; Teva UK Limited; Medicines360; HLL Lifecare Limited; Pregna International Ltd.; DKT WomanCare Global; SMB Corporation of India; Oy Leiras; OCON Healthcare; Bayer Healthcare Pharmaceuticals; CooperSurgical Inc.; Mithra Pharmaceuticals; Shanghai Dahua Medical Apparatus Co. Ltd.; Beijing Zizhu Pharmaceutical Co. Ltd.; Shanghai Jiansheng Medical Devices Co. Ltd.; Zhejiang Xianju Pharmaceutical Co. Ltd.; Shanghai Chuangling Medical Devices Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hormonal Intrauterine Devices (IUDs) market report include:- Bayer AG
- Organon & Companies
- Gedeon Richter Plc
- Meril Life Science Pvt Ltd.
- Teva UK Limited
- Medicines360
- HLL Lifecare Limited
- Pregna International Ltd.
- DKT WomanCare Global
- SMB Corporation of India
- Oy Leiras
- OCON Healthcare
- Bayer Healthcare Pharmaceuticals
- CooperSurgical Inc.
- Mithra Pharmaceuticals
- Shanghai Dahua Medical Apparatus Co. Ltd.
- Beijing Zizhu Pharmaceutical Co. Ltd.
- Shanghai Jiansheng Medical Devices Co. Ltd.
- Zhejiang Xianju Pharmaceutical Co. Ltd.
- Shanghai Chuangling Medical Devices Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.18 Billion |
| Forecasted Market Value ( USD | $ 4.74 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
